ALNYLAM PHARMACEUTICALS, INC. 10-Q filing
Filed 2025-10-30 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001628280-25-047345
- Form type
- 10-Q
- CIK
- 0001178670
- Primary document
- https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ALNYLAM PHARMACEUTICALS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.6B | - | - |
| Cost Of Revenue | $409.4M | - | - |
| Operating Income | $369.9M | - | - |
| Net Income | $127.3M | - | - |
| Eps Basic | 0.98 | - | - |
| Eps Diluted | 0.95 | - | - |
| Cash And Equivalents | $1.5B | - | - |
| Total Assets | $4.9B | - | - |
| Total Liabilities | $4.6B | - | - |
| Shareholders Equity | $233.9M | - | - |
| Operating Cash Flow | $360.5M | - | - |
| Capital Expenditures | $35.4M | - | - |